Literature DB >> 19147555

De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Stephen M Wiesner1, Stacy A Decker, Jon D Larson, Katya Ericson, Colleen Forster, Jose L Gallardo, Chunmei Long, Zachary L Demorest, Edward A Zamora, Walter C Low, Karen SantaCruz, David A Largaespada, John R Ohlfest.   

Abstract

Spontaneous mouse models of cancer show promise to more accurately recapitulate human disease and predict clinical efficacy. Transgenic mice or viral vectors have been required to generate spontaneous models of glioma, a lethal brain tumor, because nonviral gene transfer is typically transient. To overcome this constraint, we used the Sleeping Beauty transposable element to achieve chromosomal integration of human oncogenes into endogenous brain cells of immunocompetent mice. Genetically engineered, spontaneous brain tumors were induced with plasmid DNA in a matter of weeks in three separate mouse strains. The phenotype of tumors was influenced by the combination of oncogenes delivered, resembling human astrocytoma or glioblastoma in the majority of cases. At least five different genes can be cotransfected simultaneously including reporters, allowing measurement of tumor viability by in vivo imaging. This model can accelerate brain tumor research in a variety of ways such as generation of "humanized" models for high throughput drug screening and candidate gene validation with exceptional speed and flexibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147555      PMCID: PMC2701484          DOI: 10.1158/0008-5472.CAN-08-1800

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma.

Authors:  John R Ohlfest; Zachary L Demorest; Yasuhiko Motooka; Isabelita Vengco; Seunguk Oh; Eleanor Chen; Frank A Scappaticci; Rachel J Saplis; Stephen C Ekker; Walter C Low; Andrew B Freese; David A Largaespada
Journal:  Mol Ther       Date:  2005-09-16       Impact factor: 11.454

2.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.

Authors:  Ross A Dickins; Michael T Hemann; Jack T Zilfou; David R Simpson; Ingrid Ibarra; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2005-10-02       Impact factor: 38.330

3.  Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse.

Authors:  Lara S Collier; Corey M Carlson; Shruthi Ravimohan; Adam J Dupuy; David A Largaespada
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

4.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

5.  Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation.

Authors:  Andrew Xiao; Chaoying Yin; Chunyu Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Terry Van Dyke
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

6.  Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse.

Authors:  Corey M Carlson; Joel L Frandsen; Nicole Kirchhof; R Scott McIvor; David A Largaespada
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-14       Impact factor: 11.205

Review 7.  Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies.

Authors:  Stephen M Wiesner; Andrew Freese; John R Ohlfest
Journal:  Neurosurg Focus       Date:  2005-10-15       Impact factor: 4.047

8.  Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.

Authors:  Lene Uhrbom; Edward Nerio; Eric C Holland
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

9.  Bioluminescence technology for imaging cell proliferation.

Authors:  Hiroyuki Momota; Eric C Holland
Journal:  Curr Opin Biotechnol       Date:  2005-11-02       Impact factor: 9.740

10.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

View more
  81 in total

1.  Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells.

Authors:  Xin Huang; Kari Haley; Marianna Wong; Hongfeng Guo; Changming Lu; Andrew Wilber; Xianzheng Zhou
Journal:  Hum Gene Ther       Date:  2010-10-19       Impact factor: 5.695

2.  Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors.

Authors:  V Bodempudi; J R Ohlfest; K Terai; E A Zamora; R I Vogel; K Gupta; R P Hebbel; A Z Dudek
Journal:  Cancer Gene Ther       Date:  2010-08-20       Impact factor: 5.987

Review 3.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

4.  Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Authors:  Gregory J Baker; Maria G Castro; Pedro R Lowenstein
Journal:  J Vis Exp       Date:  2015-11-28       Impact factor: 1.355

Review 5.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

6.  Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.

Authors:  Mitsugu Fujita; Michael E Scheurer; Stacy A Decker; Heather A McDonald; Gary Kohanbash; Edward R Kastenhuber; Hisashi Kato; Melissa L Bondy; John R Ohlfest; Hideho Okada
Journal:  Clin Cancer Res       Date:  2010-05-14       Impact factor: 12.531

Review 7.  New approaches for modelling sporadic genetic disease in the mouse.

Authors:  Elizabeth M C Fisher; Eva Lana-Elola; Sheona D Watson; George Vassiliou; Victor L J Tybulewicz
Journal:  Dis Model Mech       Date:  2009 Sep-Oct       Impact factor: 5.758

8.  CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice.

Authors:  Mingming Gao; Dexi Liu
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

Review 9.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

Review 10.  Gene therapy for brain tumors: basic developments and clinical implementation.

Authors:  Hikmat Assi; Marianela Candolfi; Gregory Baker; Yohei Mineharu; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.